These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 26694250)
1. Preferentially Expressed Antigen in Melanoma (PRAME) and the PRAME Family of Leucine-Rich Repeat Proteins. Hermes N; Kewitz S; Staege MS Curr Cancer Drug Targets; 2016; 16(5):400-14. PubMed ID: 26694250 [TBL] [Abstract][Full Text] [Related]
2. Preferentially expressed antigen of melanoma (PRAME) in the development of diagnostic and therapeutic methods for hematological malignancies. Matsushita M; Yamazaki R; Ikeda H; Kawakami Y Leuk Lymphoma; 2003 Mar; 44(3):439-44. PubMed ID: 12688312 [TBL] [Abstract][Full Text] [Related]
3. PRAME expression is not associated with down-regulation of retinoic acid signaling in primary acute myeloid leukemia. Steinbach D; Pfaffendorf N; Wittig S; Gruhn B Cancer Genet Cytogenet; 2007 Aug; 177(1):51-4. PubMed ID: 17693191 [TBL] [Abstract][Full Text] [Related]
4. The PRAME family of cancer testis antigens is essential for germline development and gametogenesis†. Kern CH; Yang M; Liu WS Biol Reprod; 2021 Aug; 105(2):290-304. PubMed ID: 33880503 [TBL] [Abstract][Full Text] [Related]
5. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Epping MT; Wang L; Edel MJ; Carlée L; Hernandez M; Bernards R Cell; 2005 Sep; 122(6):835-47. PubMed ID: 16179254 [TBL] [Abstract][Full Text] [Related]
6. Tumor antigen PRAME is up-regulated by MZF1 in cooperation with DNA hypomethylation in melanoma cells. Lee YK; Park UH; Kim EJ; Hwang JT; Jeong JC; Um SJ Cancer Lett; 2017 Sep; 403():144-151. PubMed ID: 28634046 [TBL] [Abstract][Full Text] [Related]
7. Knock-down of PRAME increases retinoic acid signaling and cytotoxic drug sensitivity of Hodgkin lymphoma cells. Kewitz S; Staege MS PLoS One; 2013; 8(2):e55897. PubMed ID: 23409080 [TBL] [Abstract][Full Text] [Related]
8. BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients. De Carvalho DD; Binato R; Pereira WO; Leroy JM; Colassanti MD; Proto-Siqueira R; Bueno-Da-Silva AE; Zago MA; Zanichelli MA; Abdelhay E; Castro FA; Jacysyn JF; Amarante-Mendes GP Oncogene; 2011 Jan; 30(2):223-33. PubMed ID: 20838376 [TBL] [Abstract][Full Text] [Related]
9. Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy. Griffioen M; Kessler JH; Borghi M; van Soest RA; van der Minne CE; Nouta J; van der Burg SH; Medema JP; Schrier PI; Falkenburg JH; Osanto S; Melief CJ Clin Cancer Res; 2006 May; 12(10):3130-6. PubMed ID: 16707612 [TBL] [Abstract][Full Text] [Related]
12. PRAME-induced inhibition of retinoic acid receptor signaling-mediated differentiation--a possible target for ATRA response in AML without t(15;17). Bullinger L; Schlenk RF; Götz M; Botzenhardt U; Hofmann S; Russ AC; Babiak A; Zhang L; Schneider V; Döhner K; Schmitt M; Döhner H; Greiner J Clin Cancer Res; 2013 May; 19(9):2562-71. PubMed ID: 23444226 [TBL] [Abstract][Full Text] [Related]
13. PRAME peptide-specific CD8 Matko S; Manderla J; Bonsack M; Schmitz M; Bornhauser M; Tonn T; Odendahl M Eur J Immunol; 2018 Aug; 48(8):1400-1411. PubMed ID: 29738081 [TBL] [Abstract][Full Text] [Related]
14. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. van Baren N; Chambost H; Ferrant A; Michaux L; Ikeda H; Millard I; Olive D; Boon T; Coulie PG Br J Haematol; 1998 Sep; 102(5):1376-9. PubMed ID: 9753074 [TBL] [Abstract][Full Text] [Related]
15. Tumor-associated antigen preferentially expressed antigen of melanoma (PRAME) induces caspase-independent cell death in vitro and reduces tumorigenicity in vivo. Tajeddine N; Gala JL; Louis M; Van Schoor M; Tombal B; Gailly P Cancer Res; 2005 Aug; 65(16):7348-55. PubMed ID: 16103086 [TBL] [Abstract][Full Text] [Related]
17. Development of a New Highly Selective Monoclonal Antibody against Preferentially Expressed Antigen in Melanoma (PRAME) and Identification of the Target Epitope by Bio-Layer Interferometry. Sivaccumar JP; Leonardi A; Iaccarino E; Corvino G; Sanguigno L; Chambery A; Russo R; Valletta M; Latino D; Capasso D; Doti N; Ruvo M; Sandomenico A Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804612 [TBL] [Abstract][Full Text] [Related]
18. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma. Gezgin G; Luk SJ; Cao J; Dogrusöz M; van der Steen DM; Hagedoorn RS; Krijgsman D; van der Velden PA; Field MG; Luyten GPM; Szuhai K; Harbour JW; Jordanova ES; Heemskerk MHM; Jager MJ JAMA Ophthalmol; 2017 Jun; 135(6):541-549. PubMed ID: 28448663 [TBL] [Abstract][Full Text] [Related]
19. Tumor associated antigen PRAME is a marker of favorable prognosis in childhood acute myeloid leukemia patients and modifies the expression of S100A4, Hsp 27, p21, IL-8 and IGFBP-2 in vitro and in vivo. Tajeddine N; Louis M; Vermylen C; Gala JL; Tombal B; Gailly P Leuk Lymphoma; 2008 Jun; 49(6):1123-31. PubMed ID: 18452107 [TBL] [Abstract][Full Text] [Related]
20. Subcellular localization of the mouse PRAMEL1 and PRAMEX1 reveals multifaceted roles in the nucleus and cytoplasm of germ cells during spermatogenesis. Liu WS; Lu C; Mistry BV Cell Biosci; 2021 Jun; 11(1):102. PubMed ID: 34074333 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]